...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Utilization of Neoadjuvant Intensity-modulated Radiation Therapy for Rectal Cancer in the United States
【24h】

Utilization of Neoadjuvant Intensity-modulated Radiation Therapy for Rectal Cancer in the United States

机译：Neoadjuvant强度调节放射治疗在美国直肠癌的利用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Advances in technology have expanded the use of intensity-modulated radiotherapy (IMRT). The goal of this study was to investigate trends in the utilization of IMRT for rectal cancer (RC) in USA. Materials and Methods: The National Cancer Database was queried for RC patients receiving neoadjuvant chemoradiotherapy with either IMRT or three-dimensional conformal radiation therapy (3DCRT). Differences in factors associated with receipt of 3DCRT versus IMRT were determined and temporal trends were analyzed. Results: From 2005 to 2009, IMRT utilization increased, but remained constant and roughly equivalent to 3DCRT from 2010 to 2014. Patients who received IMRT were more likely to have T4 disease (p=0.014), while patients diagnosed in 2004-2006 (p0.0001) and 2007-2008 (p=0.015) were less likely to receive IMRT. There were no significant differences in postoperative outcomes between patients receiving 3DCRT and IMRT. Conclusion: IMRT utilization initially increased, but is now used at similar frequencies to 3DCRT and offers similar short-term postoperative outcomes.
机译：背景/目的：技术进步扩展了强度调制放射疗法（IMRT）的使用。本研究的目标是调查美国IMRT用于直肠癌（RC）的趋势。材料和方法：针对接受Neoadjuvant ChemoRAdiCationapy的RC患者查询国家癌症数据库（3DCRT）。确定了与接收3DCRT与IMRT相关的因素的差异，分析了时间趋势。结果：从2005年到2009年，IMRT利用率增加，但从2010年到2010年的3DCRT仍然持续且大致相当于3DCRT。接受IMRT的患者更容易发生T4疾病（P = 0.014），而诊断为2004-2006患者（P＆LT ; 0.0001）和2007-2008（p = 0.015）不太可能接受IMRT。接受3DCRT和IMRT的患者术后结果没有显着差异。结论：IMRT利用率最初增加，但现在以类似的频率用于3DCRT，提供类似的短期术后结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号